VWF-FVIII concentrates in the treatment of inherited von Willebrand disease: A single-centre retrospective study.
(2019) Haemophilia (Print) — Vol. 25, n° 4, p. e300-e303 (2019)
Files
2019_Boban_Haemophilia.pdf
Open Access - Adobe PDF
- 277.57 KB
Details
- Authors
Boban, Ana 
- Abstract
- Dear Editor, Von Willebrand disease (VWD) is the most common inherited bleeding disorder affecting both genders. Its prevalence ranges between 0.6% and 1.3% of the general population, although the number of symptomatic VWD patients appears much lower, comprised between 0.005% and 0.01%.1 VWD is a heterogeneous bleeding disorder caused by quantitative or qualitative defects of von Willebrand factor (VWF), with an impact on both primary and secondary haemostasis and variable clinical presentation. A partial quantitative defect of VWF is present in Type 1 and absolute in Type 3 VWD. Concerning Type 2 VWD, this condition is characterized by various qualitative defects of VWF, further subdivided into 2A, 2B, 2M and 2N Subtypes.2 Accordingly, the clinical presentation of VWD can range from asymptomatic individuals to patients with severe spontaneous haemophilia‐like joint bleeding, while the most common symptoms comprise mucocutaneous bleeding and bleeding from minor wounds, menorrhagia and haemorrhages following surgery or dental extractions. [...]
- Affiliations
Citations
Boban, A., Lambert, C., & Hermans, C. (2019). VWF-FVIII concentrates in the treatment of inherited von Willebrand disease: A single-centre retrospective study. Haemophilia (Print), 25(4), e300-e303. https://doi.org/10.1111/hae.13779 (Original work published 2019)